NeoGenomics, Inc. (NASDAQ:NEO) has earned an average rating of “Buy” from the thirteen analysts that are presently covering the stock, MarketBeat reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and ten have assigned a buy recommendation to the company. The average 1-year target price among brokerages that have covered the stock in the last year is $51.65.
NEO has been the topic of a number of research analyst reports. The Goldman Sachs Group initiated coverage on NeoGenomics in a report on Thursday, June 3rd. They issued a “buy” rating and a $55.00 target price on the stock. Craig Hallum increased their price target on NeoGenomics from $50.00 to $65.00 and gave the company a “buy” rating in a research note on Thursday, February 25th. Zacks Investment Research cut NeoGenomics from a “hold” rating to a “sell” rating in a research note on Wednesday, April 28th. Morgan Stanley increased their price target on NeoGenomics from $46.00 to $64.00 and gave the company an “overweight” rating in a research note on Thursday, February 25th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $65.00 price target on shares of NeoGenomics in a research note on Friday, April 16th.
NASDAQ:NEO traded up $0.67 during trading hours on Friday, reaching $42.58. 5,193 shares of the company were exchanged, compared to its average volume of 649,017. The firm has a 50 day moving average of $44.39. The firm has a market capitalization of $5.02 billion, a P/E ratio of -531.38 and a beta of 0.69. NeoGenomics has a 1-year low of $25.67 and a 1-year high of $61.57. The company has a debt-to-equity ratio of 0.63, a current ratio of 13.91 and a quick ratio of 13.60.
In other NeoGenomics news, insider Robert J. Shovlin sold 130,604 shares of the stock in a transaction dated Tuesday, May 25th. The stock was sold at an average price of $39.31, for a total transaction of $5,134,043.24. Following the completion of the sale, the insider now directly owns 249,914 shares in the company, valued at approximately $9,824,119.34. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider George Cardoza sold 169,230 shares of the stock in a transaction dated Wednesday, June 2nd. The stock was sold at an average price of $40.39, for a total value of $6,835,199.70. Following the sale, the insider now owns 207,879 shares of the company’s stock, valued at $8,396,232.81. The disclosure for this sale can be found here. 4.70% of the stock is owned by company insiders.
A number of institutional investors have recently modified their holdings of the business. Sunbelt Securities Inc. grew its holdings in NeoGenomics by 5.3% during the 1st quarter. Sunbelt Securities Inc. now owns 15,111 shares of the medical research company’s stock worth $729,000 after acquiring an additional 756 shares during the period. Principal Financial Group Inc. grew its holdings in NeoGenomics by 4.7% during the 1st quarter. Principal Financial Group Inc. now owns 851,760 shares of the medical research company’s stock worth $41,081,000 after acquiring an additional 38,309 shares during the period. Teachers Retirement System of The State of Kentucky grew its holdings in NeoGenomics by 12.1% during the 1st quarter. Teachers Retirement System of The State of Kentucky now owns 31,400 shares of the medical research company’s stock worth $1,514,000 after acquiring an additional 3,400 shares during the period. Oppenheimer Asset Management Inc. grew its holdings in NeoGenomics by 1.1% during the 1st quarter. Oppenheimer Asset Management Inc. now owns 25,443 shares of the medical research company’s stock worth $1,227,000 after acquiring an additional 287 shares during the period. Finally, Millennium Management LLC grew its holdings in NeoGenomics by 726.5% during the 1st quarter. Millennium Management LLC now owns 262,736 shares of the medical research company’s stock worth $12,672,000 after acquiring an additional 230,947 shares during the period. Hedge funds and other institutional investors own 90.82% of the company’s stock.
NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. It operates in two segments, Clinical Services and Pharma Services. The company offers testing services to hospitals, reference labs, pathologists, oncologists, clinicians, pharmaceutical firms, and researchers It provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains.
Featured Article: How is the discount rate different from the Federal Funds rate?
Receive News & Ratings for NeoGenomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeoGenomics and related companies with MarketBeat.com's FREE daily email newsletter.